Telemedicine flexibilities for prescribing buprenorphine remain in effect through December 31, 2026, under the DEA’s Fourth Temporary Extension. Clinicians can still conduct audio-only encounters for patients starting FDA-approved buprenorphine for opioid use disorder, issue an initial six-month supply without a prior in-person visit, and rely on either the temporary extension or the newer Two Final Rules, whichever fits their practice. Details on both paths sit in the Federal Register, DEA and HHS guidance, and SAMHSA statements covered below.
TL;DR:
- Providers can prescribe a six-month supply of FDA-approved buprenorphine via telehealth without an in-person visit, as long as documentation and monitoring guidelines are followed.
- Both the temporary extension and the permanent Two Final Rules permit audio-only encounters, but practitioners must document modality reasons and complete PDMP and pharmacist verification steps.
- State laws may impose stricter rules or additional licensure requirements, so verifying patient location and legal authority before cross-jurisdiction prescribing is essential.
- Consistent documentation of PDMP checks, encounter modality, and pharmacy verification is critical to withstand audits and minimize liability risks.
- Telehealth buprenorphine prescribing at Diamond Wellness adheres to federal requirements, allowing same-day treatment access with secure remote evaluations and proper record keeping.
Table of Contents
- DEA Telemedicine Buprenorphine Rules 2026: The Legal Landscape
- Buprenorphine Prescribing Rules Providers Need to Follow
- A Compliance Checklist for Telemedicine Buprenorphine Encounters
- State Law and Cross-Jurisdiction Prescribing Checks
- Diversion Control and Documentation That Holds Up to Audit
- What Compliant Telehealth MAT Looks Like at Diamond Wellness
- Buprenorphine Dosage Rules Under the 2026 Telemedicine Framework
- Who Qualifies for Buprenorphine Treatment via Telemedicine
- Provider Liability Considerations in Telehealth Buprenorphine Care
- Integrating Telemedicine Buprenorphine Prescribing With Broader SUD Treatment
- Why the 2026 Extension Deserves More Attention Than It’s Getting
- Schedule Telehealth MAT Care With Diamond Wellness in New Hampshire
- Sources
- FAQ
DEA Telemedicine Buprenorphine Rules 2026: The Legal Landscape
Two separate regulatory tracks govern telehealth buprenorphine prescribing in 2026, and providers need to know both exist. The first is the Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities, running January 1 through December 31, 2026. It amends 21 CFR 1307.41 and 42 CFR 12.1, letting DEA-registered practitioners prescribe Schedule II through V controlled substances via telemedicine, including audio-only visits for FDA-approved buprenorphine treating opioid use disorder.
The second track is a pair of permanent rules: Expansion of Buprenorphine Treatment via Telemedicine Encounter and a related rule on continuity of care for VA patients. Both were published January 17, 2025, and took effect December 31, 2025, after a delayed effective date. These Two Final Rules impose more specific requirements than the temporary extension, particularly around PDMP review and pharmacist verification.
Here’s the part many practices miss: providers eligible under the Two Final Rules can still choose to operate under the temporary extension when it’s less restrictive. The DEA press release confirms this dual-authority setup is intentional, not a drafting oversight. Practices should document which authority they’re relying on for each patient, since audit trails need to reflect a consistent, defensible choice rather than an ad hoc mix.
Buprenorphine Prescribing Rules Providers Need to Follow
The operational details matter more than the headline extension date. Four provisions do the heavy lifting for day-to-day telehealth buprenorphine prescribing:
- Audio-only encounters are allowed for initiating FDA-approved buprenorphine for OUD, without requiring a prior in-person or video evaluation. Document why audio-only was used (patient preference, access barriers, connectivity) rather than assuming the modality speaks for itself.
- An initial six-month supply is permitted via telemedicine before any in-person visit is required, structured as either one prescription or a series across the six-month window depending on clinical judgment.
- PDMP review is mandatory before issuing a buprenorphine prescription. Providers must check the prescription drug monitoring program for the state where the patient is physically located, then annotate the date and time of that review in the chart.
- If the state PDMP is temporarily unavailable, current guidance allows a short-term renewal while documenting the attempted PDMP check, so treatment doesn’t lapse over a database outage.
- Pharmacists must verify patient identity before filling a telehealth buprenorphine prescription, which means prescribers should flag telehealth-originated scripts clearly so pharmacy staff know to apply that extra verification step.
These four requirements come straight from the buprenorphine telemedicine final rule, and they apply regardless of which of the two regulatory paths a practice is operating under.
A Compliance Checklist for Telemedicine Buprenorphine Encounters
Turning regulatory text into a repeatable workflow keeps a clinic audit-ready without slowing down patient care. Run through this sequence for every telehealth buprenorphine encounter:
- Verify DEA registration status and state licensure cover the patient’s location, referencing 21 CFR 1307.41 for the practitioner conditions that apply.
- Document a legitimate medical purpose, meaning the clinical assessment should look like what you’d document for an in-person OUD evaluation, not an abbreviated version.
- Run the PDMP check for the patient’s state and log the exact date and time in the chart. If the PDMP is down, note the attempted check and the fallback short-term renewal.
- Record the modality used (audio-only or audio-video) along with the patient’s stated reason when audio-only was chosen.
- Flag the prescription for pharmacist identity verification so the dispensing pharmacy knows to apply that step before filling.
- Retain records per 21 CFR Part 1306 and whatever your state board requires, whichever standard is stricter.
Pro Tip: Build a standing EHR template with checkboxes for “PDMP reviewed [date/time],” “modality documented,” and “pharmacy notified for ID verification.” Clinics that standardize this into the note structure catch missing documentation before the encounter closes, not during an audit six months later.
State Law and Cross-Jurisdiction Prescribing Checks
Federal flexibilities set a floor, not a ceiling. Several states impose stricter telehealth prescribing rules or additional licensure requirements, and where state law is more restrictive, it controls. The DEA has been clear on this point in its own guidance: extensions don’t waive obligations under state law.
Before prescribing across state lines, confirm three things. First, verify the patient’s physical location at the time of the visit, since that determines which state’s rules and which PDMP apply. Second, check whether that state restricts audio-only prescribing or requires an in-person visit sooner than federal rules mandate. Third, confirm your own license permits practicing into that state, and whether any special registration applies.

When state and federal rules conflict, or when a patient’s situation falls into a gray area, loop in institutional legal counsel or the relevant state board before proceeding. That five-minute call is cheaper than an unwinding a compliance problem later.
Diversion Control and Documentation That Holds Up to Audit
Telehealth doesn’t change what diversion risk looks like. It changes how you have to document your response to it. Every buprenorphine telemedicine encounter should include a written clinical rationale and a monitoring plan specific to that patient, not a boilerplate note copied across charts.
Use PDMP data as a routine check, not a red-flag-only tool, and consider urine drug screening or collateral contact with a pharmacy or family member when something doesn’t add up clinically. If you have concerns about diversion, limit prescription quantities and coordinate directly with the dispensing pharmacy rather than issuing the full six-month allowance by default. Keep records long enough to satisfy both 21 CFR Part 1306 and your state’s retention rules, and structure your charting so a reviewer can reconstruct the PDMP check, the modality decision, and the pharmacist verification without asking you to remember it six months later.
What Compliant Telehealth MAT Looks Like at Diamond Wellness
A telehealth buprenorphine visit at Diamond Wellness follows the sequence regulators expect: intake and history review, a secure video or audio-only clinical evaluation depending on patient need, a PDMP check for the patient’s New Hampshire location logged with date and time, and a prescription issued within the six-month initial-supply allowance. The prescribing provider then coordinates with the patient’s pharmacy so identity verification happens before the medication is filled. It’s the same medication assisted treatment workflow Diamond Wellness has run for New Hampshire patients, built around the compliance steps outlined above rather than around shortcuts.
Buprenorphine Dosage Rules Under the 2026 Telemedicine Framework
None of the 2026 telemedicine rules change buprenorphine’s underlying dosage or prescribing limits. What they change is how a patient can get started and how long that start can last without an in-person visit. The initial six-month supply allowance is about duration of the telehealth-only period, not a dosage ceiling. Dosing decisions, titration, and any conversion between formulations still follow standard clinical practice and FDA labeling for the specific buprenorphine product prescribed.
A common misreading treats “six-month supply” as permission to prescribe at a higher dose than usual because the visit was remote. That’s not what the rule says. The buprenorphine telemedicine final rule addresses access and encounter modality, not maximum daily dose, and prescribers remain bound by the same clinical standards they’d apply in person.
Where confusion tends to surface is with combination products (buprenorphine/naloxone) versus buprenorphine monoproduct formulations, since patients sometimes assume telehealth rules apply differently to each. They don’t. The modality and supply-duration allowances apply to FDA-approved buprenorphine for OUD generally; the clinical judgment about which formulation and dose fits a given patient sits entirely with the prescriber, informed by the same factors that would guide an in-person taper or induction protocol.
Who Qualifies for Buprenorphine Treatment via Telemedicine
Eligibility for telehealth buprenorphine prescribing hinges on clinical presentation, not on a special telehealth-only category of patient. Anyone with an opioid use disorder diagnosis who would ordinarily be a candidate for buprenorphine treatment can generally be evaluated and started via telemedicine under the current framework, provided the encounter meets the same clinical documentation standard as an in-person visit.
New patients without an existing relationship with the prescriber can be started via audio-only or video telehealth for the initial six-month period. That’s a meaningful shift from the pre-pandemic Ryan Haight Act framework, which generally required an in-person evaluation before controlled substance prescribing could begin. The 2026 flexibilities remove that barrier specifically for FDA-approved buprenorphine treating OUD, while leaving intact the prescriber’s obligation to confirm the diagnosis supports treatment.
Patient location matters just as much as diagnosis. Because PDMP review and state telehealth prescribing rules attach to where the patient is physically located during the encounter, a patient who travels out of state mid-treatment can create a compliance gap if the prescriber doesn’t re-verify location and applicable state rules. Practices serving patients near state lines should build a location-confirmation step into every visit, not just the first one.
Provider Liability Considerations in Telehealth Buprenorphine Care
Liability exposure in telehealth buprenorphine prescribing tracks closely with documentation quality, not with the fact that the visit happened remotely. A malpractice claim tied to a telehealth OUD encounter typically turns on whether the clinical assessment, PDMP review, and monitoring plan look as thorough as they would have in person, so gaps in charting are where real exposure lives.
Practices reduce that exposure by treating every telehealth buprenorphine visit as a full clinical encounter rather than an abbreviated check-in. That means documenting the same history, risk assessment, and follow-up plan you’d expect from an in-person OUD visit, plus the added telehealth-specific elements: modality choice, PDMP timestamp, and pharmacist coordination. Malpractice carriers and defense attorneys reviewing a telehealth case will look for those elements specifically, since their absence is what turns a routine audit into a liability question.
Providers relying on the temporary extension should also document which regulatory authority (the Fourth Temporary Extension or the Two Final Rules) governed a given prescription, since inconsistent reliance on different standards across similar patients can itself look like a red flag during review. A care coordination approach that logs follow-up touchpoints and monitoring consistently across a patient panel gives both clinical and legal teams a cleaner record to stand on.

Integrating Telemedicine Buprenorphine Prescribing With Broader SUD Treatment
Buprenorphine prescribing rarely stands alone as effective OUD treatment, and the 2026 telemedicine rules don’t change that clinical reality. Prescribers operating via telehealth should maintain the same referral pathways to counseling, peer support, and behavioral health services that in-person MAT programs use, since medication without psychosocial support tends to produce weaker long-term outcomes.
Telehealth actually strengthens some of these connections rather than weakening them. A patient who can’t easily travel for weekly counseling can often manage a video therapy session more consistently than an in-person one, and a prescriber running both medical and behavioral telehealth visits can coordinate care more tightly because the records live in one system. Practices offering both addiction treatment and prescribing under one roof avoid the referral drop-off that happens when a patient is handed a phone number and left to schedule elsewhere.
Documentation should reflect that integration explicitly. A chart note that shows the prescriber’s awareness of a patient’s counseling attendance, or a documented referral when a patient isn’t yet connected to psychosocial support, demonstrates the kind of coordinated care federal guidance assumes is happening behind every telehealth buprenorphine prescription.
Why the 2026 Extension Deserves More Attention Than It’s Getting
Most coverage of the Fourth Temporary Extension treats it as a footnote: flexibilities continue, nothing to see here. That undersells what’s actually happening. DEA and HHS built a full year of regulatory runway specifically so providers wouldn’t face a “telemedicine cliff” while the agencies work out a permanent Special Registration process. That’s not a minor bureaucratic detail. It’s the difference between predictable practice planning and a scramble every few months to figure out what’s still legal.
The bigger miss in most guidance is treating the temporary extension and the Two Final Rules as competing options rather than a genuine dual-track system. Providers eligible under the Two Final Rules can still lean on the temporary extension when it’s less burdensome, and plenty will do exactly that through 2026. What conventional advice underplays is the documentation discipline this requires: picking one authority per patient and sticking to it on paper.
If there’s one priority for 2026, it’s this: build the PDMP annotation, modality logging, and pharmacist-notification habits into your workflow now, before a permanent rule locks in requirements you haven’t practiced yet.
— Diamond Wellness
Schedule Telehealth MAT Care With Diamond Wellness in New Hampshire
Diamond Wellness runs its telehealth buprenorphine program exactly the way the 2026 federal rules require: PDMP checks logged for every encounter, pharmacist coordination before any prescription is filled, and full clinical documentation whether the visit happens by video or audio-only.

For New Hampshire patients who’ve been putting off treatment because a nearby provider has a long wait list or because getting to an office visit feels like one more barrier, that’s the practical advantage: a licensed New Hampshire nurse practitioner who can evaluate, prescribe, and follow up entirely through secure telehealth, without sacrificing the thoroughness a compliant program requires. Same-day appointments mean you’re not waiting weeks to start treatment once you’ve decided you’re ready. If you’re looking to begin or continue medication assisted treatment, the next step is straightforward: schedule an appointment directly through Diamond Wellness and get a visit on the calendar this week.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Sources
- Fourth Temporary Extension of COVID-19 Telemedicine Flexibilities for Prescription of Controlled Medications (Federal Register)
- DEA Extends Telemedicine Flexibilities to Ensure Continued Access to Care
- Expansion of Buprenorphine Treatment via Telemedicine Encounter (Federal Register)
FAQ
What are the new rules for buprenorphine prescribing in 2026?
Telemedicine flexibilities continue through December 31, 2026, under the DEA’s Fourth Temporary Extension, allowing audio-only encounters and an initial six-month supply of FDA-approved buprenorphine for OUD without a prior in-person visit.
What are the updated telehealth guidelines for controlled substances in 2026?
DEA-registered practitioners can prescribe Schedule II through V controlled substances via telemedicine under the Fourth Temporary Extension, while a separate set of permanent rules governs buprenorphine specifically with added PDMP and pharmacist verification requirements.
Can buprenorphine be prescribed via telemedicine without an in-person visit?
Yes. Both the temporary extension and the Two Final Rules allow an initial six-month supply of buprenorphine for OUD via telemedicine, including audio-only encounters, before any in-person evaluation is required.
What changed with DEA controlled substance telehealth flexibility for 2026?
The main change is the Fourth Temporary Extension itself, extending the same allowances providers relied on since the COVID-19 public health emergency, now running alongside the newer Two Final Rules that took effect December 31, 2025.
Does Diamond Wellness offer buprenorphine treatment through telehealth in New Hampshire?
Yes. Diamond Wellness provides medication assisted treatment via secure telehealth for New Hampshire patients, following the PDMP review and pharmacist verification steps required under current federal rules.
Recommended
Disclaimer: This article is intended for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a licensed mental health professional or qualified healthcare provider regarding any questions you may have about a medical condition or treatment options.

